According to intelligence firm Ameco Research, the sector has a robust projected compound annual growth rate of 10.2% to 2027
Prebiotic developer Clasado Biosciences has predicted growth ahead for the functional gummy sector, along with the potential for prebiotics in this product segment.
According to intelligence firm Ameco Research, the sector has a robust projected compound annual growth rate of 10.2% to 2027. Clasado says it has also observed a significant increase in global demand for gummy supplements.
David Mharakurwa, Director of Sales APAC & MEA at Clasado Biosciences, said: “In conversation with our customers, we are seeing functional gummies becoming a much more common sight in the global market, with Europe and North America being particularly pronounced. Consumer demand is clearly there, and with gummy formats able to command a price premium over capsule and tablet counterparts in markets such as Europe and Asia, formulators in the health and nutrition space are certainly taking notice.
Mharakurwa says the COVID-19 pandemic has boosted consumer interest in health and wellbeing, increasing the profile of products thought to provide ‘preventative maintenance’.
“Gummies fit this role perfectly,” he says. “So it’s easy to see why they’re gathering such momentum.”
Clasado is the developer and manufacturer of Bimuno, a pre galactooligosaccharide (GOS) ingredient supported by more than 20 clinical trials.
Mharakurwa added: “The gummy market is clearly moving from strength to strength and it’s a pattern being seen across the globe. Looking towards the next step in the format’s evolution, we are expecting to see gummies pivot towards more targeted and specific health applications, in areas such as immune defence, gut health and cognition.”